Interview John Soloninka, President & CEO, HTX, Canada
John Soloninka, President & CEO of HTX, talks about his vast experience in the pharmaceutical and healthcare sector, why he feels there is much room for growth in Canada still,…
Mission
HTX supports the growth of a dynamic, prosperous Ontario medtech sector that aligns with and advances world class healthcare, enabling enhanced healthy living for its citizens.
From Invention through to Innovation to International Invoice, HTX supports emerging and established Ontario-based companies to develop, produce and commercialize innovative market-leading advanced health technologies.
John Soloninka, President & CEO of HTX, talks about his vast experience in the pharmaceutical and healthcare sector, why he feels there is much room for growth in Canada still,…
John Soloninka, President & CEO of HTX, talks about his vast experience in the pharmaceutical and healthcare sector, why he feels there is much room for growth in Canada still,…
John Soloninka, President & CEO of HTX, talks about his vast experience in the pharmaceutical and healthcare sector, why he feels there is much room for growth in Canada still,…
The co-managing partner of one of Canada’s leading IP law firms discusses the landscape for intellectual property in the pharmaceutical industry in Canada today, the legislative challenges facing his clients,…
Gino Martel explains the present environment for M&As, divestitures and out-licensing in the Canadian biotech sector, the different ways that biotech companies can commercialize their scientific successes in the current…
The director of Biotech City in Laval, close to Montreal, discusses the advantages brought on by the cluster effect, and how this has played out at Biotech City, a government…
As the only country in the G8 without an orphan drugs act, the President of Médunik, a company focused on bringing orphan drugs into the country, talks about the desperate…
An interesting perspective on the Canadian market, and its opportunities and challenges in drug registration on a regional level from the President of Triton Pharma, a company dedicated to bringing…
The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s to a niche disease, AA amyloidosis, as well as the strategic…
The CEO of MaRS Innovation, a commercialization incubator created by 16 of Toronto’s best research institutions and supported by the government, assesses Toronto’s merits as an innovation hub, and describes…
Minister Marceau addresses the changes in policy in Quebec relating to the pharmaceutical and life sciences sectors, and the incentives in place to make the state an attractive place for…
A perspective from Canada’s national health body on the future of medicine in the 21st century, from the shift to personalized medicine to streamlining regulatory and approval processes, removing duplication…
The President & CEO of Sanofi Canada talks candidly about the pros and cons of the current administrative setup of the Canadian healthcare sector; Concerto, an association in Quebec that…
Having only arrived on the market last year, the GM of Almirall in Canada explains the company’s regulatory struggles, the utilization of Almirall’s global R&D infrastructure in Canada as well…
BIOTECanada is the national trade association for Canada’s biotech industry. Andrew Casey, the group’s CEO, discusses the impact of IP regulation on emerging biotech companies, incentives for developing the sector…
See our Cookie Privacy Policy Here
